Creative Biolabs has extensive expertise in developing, identifying, and validating predictive biomarkers for GVHD. Our biomarker testing services offer precise and dependable information. We can utilize both traditional LC-MS and innovative ELISA platforms for quantification within the μg/mL range, conducting single as well as multiple analyses across various GVHD types. Creative Biolabs' established and adaptable bioassay platform, coupled with post-project support, empowers researchers to pinpoint GVHD markers linked to specific therapies and proceed with confidence.
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the most effective methods for the treatment of hematological malignancies. However, GVHD is one of the main causes of death after transplantation. Therefore, finding suitable biomarkers for GVHD, predicting the occurrence of GVHD, and prophylactic treatment before severe clinical symptoms occur is critical. Creative Biolabs has built the ideal GVHD biomarker development platform that is a fast, simple, accurate, and non-invasive system to help customers identify aGVHD and cGVHD occurrence. Our GVHD biomarkers offer a specific and sensitive indication of the disease state. Among these, biomarkers for aGVHD are valuable for diagnosing the disease, monitoring its occurrence and progression, as well as assessing prognosis and early treatment.
Fig.1 4 MicroRNA Expression in Acoustically Enriched EVs From allo-HSCT Patients.1
Chief Services
Currently, predictive biomarkers for GVHD are lacking, and predicting GVHD and guiding preventive treatment is a new strategy for many transplant patients. At present, most studies on biomarkers for GVHD are limited to animal experiments and small-sample clinical studies. Due to the heterogeneity of patients, differences in measurement time and means, different pretreatment intensities, and different prevention strategies for GVHD, there are still some differences in prediction results.
MicroRNAs (miRNAs) represent a category of non-coding RNAs approximately 20-25 nucleotides in length that exert regulatory effects by targeting mRNA degradation to modulate protein expression. Our research at Creative Biolabs has delved into understanding the involvement of animal and human miRNAs in GVHD pathogenesis while identifying potential impactful candidates like miR-423, miR199a-3p, and miR-93 as both diagnostic tools and therapeutic targets; ongoing investigations aim to elucidate their specificity and diagnostic utility.
In terms of serving as predictors for GVHD protein levels, biochemical indicators fall into three primary categories: systemic markers encompassing endothelial damage indices, such as soluble IL-2 receptor (IL-2R), and ST2; organ-specific markers predominantly related to digestive tract, liver, and skin functions; finally, a composite marker group integrates multiple elements to furnish prognostic insights on maximum severity, response to treatment, and mortality associated with GVHD.
CD4 + CD25 + Treg cells are a subset of T cells characterized by their immunosuppressive and regulatory functions. FoxP3 is specifically expressed in the cytoplasm of CD4 + CD25 + Treg cells, playing a crucial role in their differentiation, development, and maintenance of immunosuppressive function. Creative Biolabs utilizes CD4 + CD25 + FOXP3 + Treg as a biomarker for predicting the occurrence and prognosis of GVHD. Furthermore, we can alleviate the severity of GVHD observed after cord blood transplantation by utilizing FoxP3+ Treg cells within cord blood CD4+ ATs. We offer monitoring services for Treg cell levels to promptly detect excessive immunosuppression, adjust immunosuppressive therapy, and reduce adverse reactions following allo-HSCT.
There is mounting evidence indicating the significance of metabolic markers in GVHD progression. Creative Biolabs can qualitatively and quantitatively analyze metabolite phenotypes in biological samples to study the impact of GVHD on patients' metabolic state, elucidate metabolic pathways and pathogenesis, and establish a targeted system for predicting, diagnosing, treating, and prognosticating GVHD. In our labs, we primarily employ LC-MS and GC-MS methods to analyze plasma from HSCT recipients. Multiple metabolic markers have been identified in recipients with GVHD such as 2-aminobutyric acid, and 1-palmitate monoglyceride.
The Creative Biolabs Biomarker Research team focuses on drug target-GVHD biomarker research at its core, leveraging an advanced technology platform to explore mechanisms from the early stages of GVHD development through preclinical mechanism research and validation services that provide data-driven scientific support. If you are interested in our services, please feel free to contact us.
Reference
-
Lim, Hooi Ching, et al. "Development of acoustically isolated extracellular plasma vesicles for biomarker discovery in allogeneic hematopoietic stem cell transplantation." Biomarker research 9 (2021): 1-12.
For Research Use Only | Not For Clinical Use
Download our brochure